GLS and neoplasm: In this context, combining targeted ammonia metabolism intervention (e.g., using the GLS1 inhibitor CB-839) with CAR-T cell infusion not only blocks tumor cell utilization of ammonia but also enhances T cell adaptability through metabolic plasticity, thereby simultaneously alleviating the immunosuppressive microenvironment and prolonging CAR-T cell persistence (156, 159).